Freebies to Doctors: Supreme Court Asks Centre to Form Committee on a Binding Pharma Marketing Code

Case at a glance: The Supreme Court has directed the Union to set up a three-member committee to examine whether pharmaceutical marketing practices, including freebies to doctors, should be regulated by statute. As reported, it found the existing framework had “not proved entirely effective” but left the choice of regulatory model to the legislature and executive.

The petition, filed under Article 21, sought a statutory and enforceable code against unethical pharma marketing, arguing that heavy promotional spending leads doctors to over-prescribe. It cited the CBDT's allegation that the makers of Dolo-650 gave doctors freebies worth about Rs 1,000 crore, and the NMC keeping its 2023 Professional Conduct Regulations on generic prescribing in abeyance.

The Union relied on the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, which bars gifts, travel, hospitality and cash to doctors, and said it was considering the Standing Committee on Health's recommendation for a statutory code.

The Key Question Before the Court

Is the existing largely voluntary regime adequate to curb unethical pharma marketing, and should the Court direct a statutory code?

Enforcement Gaps and Separation of Powers

As reported, the Court observed that doctors who accept benefits face penalties but there is no matching statutory mechanism against pharmaceutical companies, and that what matters is implementation and enforcement.

It held that choosing the regulatory model is for the legislature and executive, so it would facilitate a consultative process rather than frame a code itself. The petitioners relied on Apex Laboratories Pvt. Ltd. v. DCIT (2022), describing the doctor-patient relationship as quasi-fiduciary.

What the Court Actually Held

• The Union must constitute a three-member committee to review the need for and form of statutory regulation, and the effectiveness of monitoring and enforcement.
• The committee must hear petitioners, intervenors and stakeholders, may consult experts, and must report within two months of its first meeting.
• The Union must take a reasoned decision at the earliest, keeping Article 21 in view.
• The UCPMP, 2024 continues to apply meanwhile; a compliance affidavit is due and the matter is listed on 29 January 2027.

Why This Judgment Matters

• It puts pharma marketing regulation back on the policy agenda.
• It links ethical marketing to the right to health under Article 21.
• It shows judicial restraint on policy design while ensuring accountability.

What Should Advocates Take Away From the Judgment?

For Health and Consumer Advocates

• Participate in the committee's consultation with evidence of prescribing patterns and marketing spend.

For Pharma Companies' Counsel

• Review compliance with the UCPMP 2024, which continues to apply.

Key Takeaways

Frequently Asked Questions

No new ban was imposed. The Court directed a committee and a reasoned decision by the Union; the existing UCPMP 2024 already bars gifts and hospitality.

Two months from its first meeting to report, as reported.

29 January 2027.

Conclusion